伊布替尼治疗下慢性淋巴细胞白血病的疾病进展：越多越糟？
Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?
作者信息
Bomben Riccardo, Zucchetto Antonella, Gentile Massimo, Gattei Valter
机构信息
Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Pordenone, Italy.
Hematology Unit, AO of Cosenza, Cosenza, Italy.
出版信息
Clin Cancer Res. 2021 Aug 15;27(16):4462-4464. doi: 10.1158/1078-0432.CCR-21-1750. Epub 2021 Jun 14.
Patients with chronic lymphocytic leukemia carrying a single hit (chromosome 17p deletion or single mutation) demonstrate excellent progression-free survival and overall survival on ibrutinib compared with cases harboring multiple hits. Testing deletion/mutation combining FISH and deep next-generation sequencing should be performed for a correct patient evaluation..
与携带多个打击因素的病例相比，携带单一打击因素（17号染色体p缺失或单基因突变）的慢性淋巴细胞白血病患者使用依鲁替尼治疗时表现出优异的无进展生存期和总生存期。应结合荧光原位杂交（FISH）和深度二代测序进行缺失/突变检测，以对患者进行正确评估。
Zotero 插件